Drug Insights

Strategically Search Nortriptyline on Synapse: A How-to Guide

29 March 2024
2 min read

Nortriptyline, a monoamine reuptake inhibitor, is a small molecule drug that exhibits its pharmacological action by targeting MATs. Eli Lilly, the pharmaceutical conglomerate, was the developer of this drug which, after a rigorous testing phase, received the green light for treating depressive disorder in November 1964. Nortriptyline belongs to the tricyclic antidepressant family and operates by bolstering the levels of neurotransmitters, such as serotonin and norepinephrine, within the brain. The drug performs its depression-fighting functions by inhibiting their reuptake, hence resulting in the alleviation of symptoms such as low mood, lack of energy and motivation, and disrupted sleep. Click on the image below to begin the exploration journey of Nortriptyline through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Novo Nordisk plans to purchase Cardior Pharmaceuticals, bolstering its portfolio in heart health management
Latest Hotspot
3 min read
Novo Nordisk plans to purchase Cardior Pharmaceuticals, bolstering its portfolio in heart health management
29 March 2024
Novo Nordisk has entered into an acquisition agreement with Cardior Pharmaceuticals, with the deal amounting to a maximum of 1.025 billion Euros.
Read →
What is Bioavailability?
"What" Series
2 min read
What is Bioavailability?
29 March 2024
Bioavailability refers to the extent and rate at which the active ingredient of a drug or nutrient is absorbed into the circulation and becomes available at the site of action within the body.
Read →
Apogee Therapeutics Begins Phase 1 Trial of APG808 for COPD and Inflammation
Latest Hotspot
3 min read
Apogee Therapeutics Begins Phase 1 Trial of APG808 for COPD and Inflammation
29 March 2024
Apogee Therapeutics has initiated dosing of initial volunteers in a Phase 1 study of their new extended-duration IL-4Rα antibody, APG808, aimed at managing Chronic Obstructive Pulmonary Disease (COPD) and various inflammatory conditions.
Read →
User-friendly Guide to Find Valsartan on Synapse
Drug Insights
2 min read
User-friendly Guide to Find Valsartan on Synapse
29 March 2024
Valsartan, a diminutive molecular compound, falls within the pharmacological group of angiotensin receptor blockers (ARBs).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.